• Corpus ID: 39529800

Technology evaluation: APC-80200, Dendreon.

@article{Rice2002TechnologyEA,
  title={Technology evaluation: APC-80200, Dendreon.},
  author={Alison Rice and Derek N. J. Hart},
  journal={Current opinion in molecular therapeutics},
  year={2002},
  volume={4 5},
  pages={
          523-7
        }
}
  • Alison Rice, D. Hart
  • Published 1 October 2002
  • Medicine, Biology
  • Current opinion in molecular therapeutics
APC-80200 (Mylovenge) has been developed for the treatment of B-cell malignancies and is currently in phase II clinical trials as a therapeutic vaccine for patients with advanced multiple myeloma. This vaccine candidate appears to be of particular benefit in patients who have received high-dose chemotherapy to reduce tumor load following stem cell rescue. APC-80200 is also being tested in patients with amyloidosis. 
DC in multiple myeloma immunotherapy.
TLDR
The background research leading to the recognition of an anti-MM immune response is reviewed, and abnormalities in DC function, potential tumor-associated Ags, and the results of clinical trials of DC immunotherapy in MM patients are discussed.
Immunology and immunotherapeutic approaches in multiple myeloma.
  • C. Schlude, P. Beckhove
  • Medicine, Biology
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
  • 2011
TLDR
Although several obstacles still need to be overcome, it appears that clinically efficient immunotherapies will become available for multiple myeloma patients in the future.
Immunotherapy in multiple myeloma – possibility or probability?
TLDR
The current understanding of immunobiology in MM is assessed, and how the different components of the immune system, such as dendritic cells, T cells and natural killer cells, may be harnessed using in‐vitro and in-vivo priming techniques are assessed.
Immunotherapy in Multiple Myeloma.
DC preparations for therapy.
This review describes and compares the different DC preparations currently under laboratory and clinical investigation as vehicles for cancer immunotherapy.
Immunotherapy of multiple myeloma: the start of a long and tortuous journey
TLDR
This review will summarize the current knowledge of the fundamental immunology of myeloma, review immunotherapy trials reported to date and discuss whether, in light of the current information, immunotherapy of multipleMyeloma is an achievable goal.
Immune suppression in multiple myeloma : strategies to overcome NK cell inhibition
TLDR
This book presents a meta-analyses of the determinants of infectious disease and its mechanisms and some of the mechanisms are explained in more detail in the second part of this chapter.